AR080892A2 - Complejo insoluble en agua, composicion farmaceutica que lo comprende, metodos para prepararla y metodo para preparar dicho complejo - Google Patents

Complejo insoluble en agua, composicion farmaceutica que lo comprende, metodos para prepararla y metodo para preparar dicho complejo

Info

Publication number
AR080892A2
AR080892A2 ARP110101253A ARP110101253A AR080892A2 AR 080892 A2 AR080892 A2 AR 080892A2 AR P110101253 A ARP110101253 A AR P110101253A AR P110101253 A ARP110101253 A AR P110101253A AR 080892 A2 AR080892 A2 AR 080892A2
Authority
AR
Argentina
Prior art keywords
complex
water insoluble
prepare
acetate
phthalate
Prior art date
Application number
ARP110101253A
Other languages
English (en)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26798138&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR080892(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR080892A2 publication Critical patent/AR080892A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Un complejo insoluble en agua que comprende un compuesto estable a la humedad y al calor, amorfo seleccionado a partir del grupo formado por saquinavir y un polímero ionico insoluble en agua que tiene un peso molecular mayor que 80.000 D, una temperatura de transicion vítrea igual o mayor que 50sC, y está seleccionado a partir del grupo formado por poliacrilato, quitosan, polímeros carboxivinílicos, ftalato acetato de polivinilo, ftalato acetato de celulosa, policianoacrilatos, ftalato de hidroxipropilmetilcelulosa, tereftalato acetato de celulosa, succinato acetato de hidroxipropilmetilcelulosa, carboximetilcelulosa e hidroxipropilcelulosa de baja sustitucion, o una mezcla de dos o más de los polímeros ionicos anteriormente descriptos, en donde el compuesto terapéuticamente activo, estable amorfo está incorporado en el complejo compuesto/polímero predominantemente en forma amorfa, de acuerdo a lo determinado por difraccion de rayos X de polvo, y está presente en el complejo insoluble en agua en no menos del 10%, en peso, y el polímero ionico está presente en el complejo en no menos del 20%, en peso. También se dan a conocer: una composicion farmacéutica que comprende dicho complejo, métodos para preparar dicha composicion, método para preparar dicho complejo y un método para estabilizar un compuesto amorfo.
ARP110101253A 1998-09-22 2011-04-13 Complejo insoluble en agua, composicion farmaceutica que lo comprende, metodos para prepararla y metodo para preparar dicho complejo AR080892A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10133698P 1998-09-22 1998-09-22
US13653199P 1999-05-28 1999-05-28

Publications (1)

Publication Number Publication Date
AR080892A2 true AR080892A2 (es) 2012-05-16

Family

ID=26798138

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP990104725A AR022096A1 (es) 1998-09-22 1999-09-20 Complejos estables de compuestos muy poco solubles
ARP110101253A AR080892A2 (es) 1998-09-22 2011-04-13 Complejo insoluble en agua, composicion farmaceutica que lo comprende, metodos para prepararla y metodo para preparar dicho complejo

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP990104725A AR022096A1 (es) 1998-09-22 1999-09-20 Complejos estables de compuestos muy poco solubles

Country Status (32)

Country Link
US (1) US6350786B1 (es)
EP (1) EP0988863B2 (es)
JP (5) JP2000095708A (es)
KR (1) KR100362019B1 (es)
CN (1) CN1201821C (es)
AR (2) AR022096A1 (es)
AT (1) ATE265232T1 (es)
AU (1) AU770745B2 (es)
BR (1) BR9904283A (es)
CA (1) CA2282906C (es)
CO (1) CO5140077A1 (es)
CZ (1) CZ300215B6 (es)
DE (1) DE69916733T3 (es)
DK (1) DK0988863T4 (es)
ES (1) ES2218918T5 (es)
HR (1) HRP990287B1 (es)
HU (1) HU228341B1 (es)
ID (1) ID24034A (es)
IL (1) IL131957A (es)
MA (1) MA26692A1 (es)
MY (1) MY124377A (es)
NO (1) NO326928B1 (es)
NZ (1) NZ337884A (es)
PE (1) PE20001049A1 (es)
PL (1) PL202757B1 (es)
PT (1) PT988863E (es)
RS (1) RS50193B (es)
RU (1) RU2240827C2 (es)
SG (1) SG97131A1 (es)
SI (1) SI0988863T2 (es)
TR (1) TR199902324A3 (es)
TW (1) TWI234465B (es)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2307482T3 (es) 1999-02-10 2008-12-01 Pfizer Products Inc. Dispersiones farmaceuticas solidas.
US6440959B1 (en) 1999-04-21 2002-08-27 Hoffman-La Roche Inc. Pyrazolobenzodiazepines
PE20010659A1 (es) * 1999-10-01 2001-06-20 Hoffmann La Roche Derivados de las pirimidin-2,4,6-trionas como inhibidores de metaloproteasas
US6313143B1 (en) * 1999-12-16 2001-11-06 Hoffmann-La Roche Inc. Substituted pyrroles
EP1301221B1 (en) * 2000-05-16 2006-02-15 Ortho-McNeil Pharmaceutical, Inc. Process for coating medical devices using super-critical carbon dioxide
US6469179B1 (en) 2000-10-03 2002-10-22 Hoffmann-La Roche Inc. Amorphous form of cell cycle inhibitor having improved solubility and bioavailability
US6482847B2 (en) * 2000-10-03 2002-11-19 Hoffmann-La Roche Inc. Amorphous form of cell cycle inhibitor having improved solubility and bioavailability
US6607784B2 (en) 2000-12-22 2003-08-19 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US6977085B2 (en) 2000-12-22 2005-12-20 Baxter International Inc. Method for preparing submicron suspensions with polymorph control
US6951656B2 (en) 2000-12-22 2005-10-04 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US8067032B2 (en) 2000-12-22 2011-11-29 Baxter International Inc. Method for preparing submicron particles of antineoplastic agents
US6884436B2 (en) 2000-12-22 2005-04-26 Baxter International Inc. Method for preparing submicron particle suspensions
US9700866B2 (en) 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
US20050048126A1 (en) 2000-12-22 2005-03-03 Barrett Rabinow Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug
US7193084B2 (en) 2000-12-22 2007-03-20 Baxter International Inc. Polymorphic form of itraconazole
US6548531B2 (en) 2001-02-09 2003-04-15 Hoffmann-La Roche Inc. Method for cancer therapy
US6716845B2 (en) 2001-03-30 2004-04-06 Hoffmann-La Roche Inc. Barbituric acid derivatives
AU2002310567B2 (en) * 2001-05-30 2005-10-20 Csir Method of encapsulating an active substance
US20030044514A1 (en) * 2001-06-13 2003-03-06 Richard Robert E. Using supercritical fluids to infuse therapeutic on a medical device
WO2002102373A1 (en) * 2001-06-15 2002-12-27 F. Hoffmann-La Roche Ag Method for administration of cancer therapeutic
HUP0400264A2 (hu) 2001-06-22 2004-08-30 Pfizer Products Inc. Alacsony oldékonyságú és/vagy savra érzékeny hatóanyagokat és semlegesített savas polimereket tartalmazó gyógyszerkészítmények és eljárás az előállításukra
CA2450957A1 (en) 2001-06-22 2003-01-03 Pfizer Products Inc. Pharmaceutical compositions of dispersions of drugs and neutral polymers
US20060003012A9 (en) 2001-09-26 2006-01-05 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems
JP2005504090A (ja) 2001-09-26 2005-02-10 バクスター・インターナショナル・インコーポレイテッド 分散体および溶媒相または液相の除去によるサブミクロンサイズ−ナノ粒子の調製
US7112340B2 (en) 2001-10-19 2006-09-26 Baxter International Inc. Compositions of and method for preparing stable particles in a frozen aqueous matrix
US20030139373A1 (en) * 2001-11-20 2003-07-24 Breimer Lars Holger Method for cancer therapy
ES2878403T3 (es) * 2002-02-01 2021-11-18 Bend Res Inc Método para preparar dispersiones de fármacos amorfas sólidas homogéneas secadas mediante pulverización utilizando aparatos de secado por pulverización modificados
RU2005103625A (ru) 2002-08-12 2005-08-20 Пфайзер Продактс Инк. (Us) Фармацевтические композиции полуупорядоченных лекарств и полимеров
DE10351087A1 (de) * 2003-10-31 2005-05-25 Bayer Technology Services Gmbh Feste Wirkstoff-Formulierung
ATE495746T1 (de) * 2003-11-14 2011-02-15 Ajinomoto Kk Feste dispersion oder medizinisches festes dispersionspräparat eines phenylalanin-derivats
WO2005046697A1 (ja) * 2003-11-14 2005-05-26 Ajinomoto Co., Inc. フェニルアラニン誘導体の徐放性経口投与製剤
KR100771411B1 (ko) * 2004-04-01 2007-10-30 에프. 호프만-라 로슈 아게 피리미딘-2,4,6-트리온의 시클로덱스트린 포접 복합체
AR049915A1 (es) * 2004-06-14 2006-09-13 Anacor Pharmaceuticals Inc Compuestos con contenido de boro y metodos de uso de los mismos
WO2006062980A2 (en) * 2004-12-07 2006-06-15 Nektar Therapeutics Stable non-crystalline formulation comprising tiagabine
CN101115469A (zh) * 2004-12-28 2008-01-30 卫材R&D管理有限公司 速崩片及其制造方法
KR101238525B1 (ko) * 2004-12-31 2013-02-28 레디 유에스 테라퓨틱스 인코포레이티드 Ｃｅｔｐ 저해제로서의 신규 벤질아민 유도체
US8604055B2 (en) 2004-12-31 2013-12-10 Dr. Reddy's Laboratories Ltd. Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
WO2006081497A2 (en) * 2005-01-27 2006-08-03 Corium International, Inc. Hydrophilic biocompatible adhesive formulations and uses
EP1690528A1 (de) * 2005-02-11 2006-08-16 Abbott GmbH & Co. KG Herstellung von Dosierungsformen mit einer festen Dispersion eines mikrokristallinen Wirkstoffs
US20080274192A1 (en) * 2005-05-19 2008-11-06 Pfizer Inc. Pharmaceutical Compositions Comprising an Amorphous Form of a Vegf-R-Inhibitor
EP1767194A1 (de) * 2005-06-09 2007-03-28 Helm AG Verfahren zur Herstellung von Adsorbaten des Drospirenons
EP2395004B1 (en) * 2005-06-22 2016-01-20 Plexxikon Inc. Pyrrolo [2,3-b]pyridine derivatives as protein kinase inhibitors
US20080031944A1 (en) * 2006-08-04 2008-02-07 Cima Labs Inc. Stabilization of lorazepam
BRPI0714265A2 (pt) * 2006-08-10 2013-04-16 Cipla Ltd composiÇço oral sàlida, processo para preparar uma composiÇço oral sàlida, uso de uma composiÇço e mÉtodo para tratar hiv
US20080107725A1 (en) * 2006-10-13 2008-05-08 Albano Antonio A Pharmaceutical Solid Dosage Forms Comprising Amorphous Compounds Micro-Embedded in Ionic Water-Insoluble Polymers
WO2008063888A2 (en) 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
WO2008079909A1 (en) * 2006-12-21 2008-07-03 Plexxikon, Inc. Pyrrolo [2,3-b] pyridines as kinase modulators
PE20081581A1 (es) * 2006-12-21 2008-11-12 Plexxikon Inc COMPUESTOS PIRROLO[2,3-b]PIRIDINAS COMO MODULADORES DE QUINASA
EP2127677A4 (en) 2006-12-27 2012-05-02 Astellas Pharma Inc AMINO ALKYL METHACRYLATE COPOLYMER FOR MAINTAINING THE SOLUBILITY OF A HEAVY WATER-SOLUBLE MEDICAMENT
CN101702878B (zh) * 2007-05-11 2012-11-28 弗·哈夫曼-拉罗切有限公司 可溶性差的药物的药物组合物
US8722736B2 (en) 2007-05-22 2014-05-13 Baxter International Inc. Multi-dose concentrate esmolol with benzyl alcohol
US8426467B2 (en) 2007-05-22 2013-04-23 Baxter International Inc. Colored esmolol concentrate
EP1997479A1 (en) * 2007-05-31 2008-12-03 Helm AG Stabilized amorphous candesartan cilexetil compositions for oral administration
CA2695004C (en) 2007-07-17 2016-01-19 Plexxikon, Inc. Compounds and methods for kinase modulation, and indications therefor
WO2009052391A1 (en) * 2007-10-19 2009-04-23 Purdue Research Foundation Solid formulations of crystalline compounds
US8632805B2 (en) * 2008-06-20 2014-01-21 Mutual Pharmaceutical Company, Inc. Controlled-release formulations, method of manufacture, and use thereof
US7794750B2 (en) * 2008-06-20 2010-09-14 Mutual Pharmaceutical Company, Inc. Controlled-release formulations, method of manufacture, and use thereof
US20100099696A1 (en) * 2008-10-16 2010-04-22 Anthony Edward Soscia Tamper resistant oral dosage forms containing an embolizing agent
KR20100073454A (ko) * 2008-12-23 2010-07-01 국립암센터 트란스글루타미나제 억제제로 사용되는 신규한 피라졸로디아제핀계 화합물, 이의 제조방법 및 이를 포함하는 조성물
MX349923B (es) * 2009-04-03 2017-08-21 Hoffmann La Roche Composiciones del ácido propano-1-sulfónico {3-[5-(4-cloro-fenil)- 1h-pirrolo [2,3-b]-piridina-3-carbonil]-2,4-difluoro-fenil]-amida y el uso de las mismas.
US8329724B2 (en) 2009-08-03 2012-12-11 Hoffmann-La Roche Inc. Process for the manufacture of pharmaceutically active compounds
ES2633317T3 (es) 2009-11-06 2017-09-20 Plexxikon, Inc. Compuestos y métodos para la modulación de quinasas, e indicaciones para ello
CN103153306A (zh) * 2010-05-31 2013-06-12 安斯泰来制药有限公司 三唑化合物的固体分散体
TR201816421T4 (tr) 2011-02-07 2018-11-21 Plexxikon Inc Kinaz modülasyonu için bileşikler ve metotlar ve bunların endikasyonları.
CN103391769A (zh) 2011-02-17 2013-11-13 霍夫曼-拉罗奇有限公司 通过热熔挤出使活性药物成分从过冷液体状态受控结晶的方法
TWI558702B (zh) 2011-02-21 2016-11-21 普雷辛肯公司 醫藥活性物質的固態形式
LT2720989T (lt) 2011-06-20 2016-11-25 H. Lundbeck A/S Deuterinti 1-piperazin-3-fenilindanai, skirti šizofrenijos gydymui
US9199967B2 (en) 2011-08-18 2015-12-01 Dr. Reddy's Laboratories Ltd. Substituted heterocyclic amine compounds as cholestryl ester-transfer protein (CETP) inhibitors
WO2013037396A1 (en) * 2011-09-12 2013-03-21 Bioneer A/S Solution of polymer in api for a solid dosage form
JP6140168B2 (ja) 2011-09-27 2017-05-31 ドクター レディズ ラボラトリーズ リミテッド アテローム性動脈硬化症の処置のために有用なコレステリルエステル転送タンパク質（ｃｅｔｐ）インヒビターとしての５−ベンジルアミノメチル−６−アミノピラゾロ［３，４−ｂ］ピリジン誘導体
JP5944514B2 (ja) * 2011-10-14 2016-07-05 アレイ バイオファーマ、インコーポレイテッド 固体分散体
MX354024B (es) * 2012-03-23 2018-02-08 Array Biopharma Inc Uso de array-380 y ar00440993 para el tratamiento de cancer de cerebro.
US20140128431A1 (en) 2012-04-03 2014-05-08 Hoffmann-Laroche Inc. Pharmaceutical composition with improved bioavailability, safety and tolerability
EP2649989B1 (en) 2012-04-13 2017-10-18 King Saud University Method for preparing a solid dispersion, solid dispersion obtained thereby and use thereof
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
JO3339B1 (ar) * 2012-09-11 2019-03-13 Shanghai Inst Pharmaceutical Ind شكل مستقر غير متبلور من الأغوميلاتين وعملية تحضيره والتركيبات الدوائية التي تحتوي عليه
KR20150084873A (ko) 2012-11-19 2015-07-22 닥터 레디스 레보러터리즈 리미티드 Cetp 억제제의 약학적 조성물
RU2015128794A (ru) * 2012-12-20 2017-01-25 КАШИВ ФАРМА, ЭлЭлСи Композиция перорально распадающейся таблетки, обеспечивающая повышенную биодоступность
CA2892025C (en) 2013-01-22 2022-02-15 F. Hoffmann-La Roche Ag Solid dispersions comprising 4-{[(2r, 3s, 4r, 5s)-4-(4-chloro-2-fluoro-phenyl)-3-(3-chloro-2-fluoro-phenyl)-4-cyano-5-(2,2-dimethyl-propyl)-pyrrolidine-2-carbonyl]-amino}-3- methoxy -benzoic acid and pharmaceutical compositions comprising same with improved bioavailability
TWI615157B (zh) 2013-02-06 2018-02-21 大塚製藥股份有限公司 包括不定形西洛他唑的固體分散劑
WO2015038376A1 (en) * 2013-09-11 2015-03-19 3M Innovative Properties Company Coating compositions, dental structures thereof and methods for generating contrast
WO2015082562A1 (en) * 2013-12-05 2015-06-11 Alrise Biosystems Gmbh Process for the production of drug formulations for oral administration
PT107846B (pt) * 2014-08-01 2019-03-22 Hovione Farm S A Produção de nano- partículas de dispersões sólidas amorfas por co-precipitação controlada
AU2015397336A1 (en) * 2015-05-29 2017-12-21 Sun Pharmaceutical Industries Limited Oral pharmaceutical composition of isotretinoin
EP3447056B1 (en) * 2016-12-13 2025-04-30 TransThera Sciences (Nanjing), Inc. Multi-kinase inhibitor compound, and crystal form and use thereof
WO2018201016A1 (en) 2017-04-28 2018-11-01 Cascadian Therapeutics, Inc. Treatment of her2 positive cancers
KR102082775B1 (ko) * 2017-05-02 2020-02-28 주식회사 삼양바이오팜 수용해도 및 생체이용율이 개선된 조성물
RU2725879C2 (ru) * 2018-07-26 2020-07-07 Федеральное государственное бюджетное образовательное учреждение высшего образования "Казанский Государственный медицинский университет" Министерства здравоохранения Российской Федерации Интерполимерный носитель для пероральных систем контролируемой доставки активных фармацевтических ингредиентов
EP3891134A1 (en) 2018-12-03 2021-10-13 H. Lundbeck A/S Prodrugs of 4-((1r,3s)-6-chloro-3-phenyl-2,3-dihydro-1h-inden-1-yl)-1,2,2-trimethylpiperazine and 4-((1/r,3s)-6-chloro-3-(phenyl-d5)-2,3-dihydro-1h-inden-1-yl)-2,2-dimethy-1-(methyl-d3)piperazine
JP7738961B2 (ja) 2020-01-24 2025-09-16 ハンダ セラピューティクス リミテッド ライアビリティ カンパニー ダサチニブの非晶質固体分散体及びその使用
CA3168680A1 (en) 2020-01-31 2021-08-05 Nanocopoeia, Llc Amorphous nilotinib microparticles and uses thereof
JP7705715B2 (ja) 2020-03-03 2025-07-10 デクセリアルズ株式会社 画像表示装置の製造方法
EP4142699A1 (en) 2020-04-30 2023-03-08 Nanocopoeia LLC Orally disintegrating tablet comprising amorphous solid dispersion of nilotinib
US11980619B2 (en) 2021-07-28 2024-05-14 Nanocopoeia, Llc Pharmaceutical compositions and crushable tablets including amorphous solid dispersions of dasatinib and uses

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS51118816A (en) * 1975-04-08 1976-10-19 Meiji Seika Kaisha Ltd A process for stabilizing non-crystalloidal solid
US4344934A (en) * 1978-11-20 1982-08-17 American Home Products Corporation Therapeutic compositions with enhanced bioavailability
JPS62155263A (ja) * 1985-11-27 1987-07-10 シンテツクス（ユ−・エス・エイ）インコ−ポレイテツド アモルフアス−ベンズイミダゾ−ル誘導体
GB8608080D0 (en) * 1986-04-02 1986-05-08 Fujisawa Pharmaceutical Co Solid dispersion composition
SK75289A3 (en) * 1988-02-10 1998-05-06 Hoffmann La Roche Substituted pyrroles, their use for producing a drug, and the drug on their base
JP2528706B2 (ja) † 1988-05-30 1996-08-28 ゼリア新薬工業株式会社 ジヒドロピリジン化合物の製剤組成物
USRE36736E (en) 1989-02-06 2000-06-13 Hoffman-La Roche Inc. Substituted pyrroles
JPH0729926B2 (ja) † 1989-07-25 1995-04-05 大塚製薬株式会社 易吸収性製剤用組成物
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
CA2108575C (en) † 1991-04-16 2002-10-22 Kouichi Nakamichi Method of manufacturing solid dispersion
US5281420A (en) 1992-05-19 1994-01-25 The Procter & Gamble Company Solid dispersion compositions of tebufelone
TW493991B (en) 1995-05-08 2002-07-11 Novartis Ag Pharmaceutical composition for oral administration of active agent having low water solubility and process for preparation of the same
GB9511220D0 (en) † 1995-06-02 1995-07-26 Glaxo Group Ltd Solid dispersions
FR2736550B1 (fr) * 1995-07-14 1998-07-24 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule
ATE240734T1 (de) * 1995-07-26 2003-06-15 Kyowa Hakko Kogyo Kk Zubereitung von xanthinderivaten als feste dispersion
WO1997008950A1 (en) † 1995-09-07 1997-03-13 Fuisz Technologies, Ltd. System for rendering substantially non-dissoluble bio-affecting agents bio-available
DE19548624A1 (de) 1995-12-23 1997-06-26 Boehringer Mannheim Gmbh Neue Barbitursäure-Derivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
JPH09208459A (ja) * 1996-02-07 1997-08-12 Eisai Co Ltd 溶解性を改良した製剤
EP0932399B1 (en) 1996-03-12 2006-01-04 PG-TXL Company, L.P. Water soluble paclitaxel prodrugs
WO1998000113A1 (en) * 1996-06-28 1998-01-08 Schering Corporation Solid solution of an antifungal agent with enhanced bioavailability
PE91598A1 (es) 1996-07-29 1998-12-24 Hoffmann La Roche Pirroles sustituidos
US6229011B1 (en) 1997-08-22 2001-05-08 Hoffman-La Roche Inc. N-aroylphenylalanine derivative VCAM-1 inhibitors
RU2208612C2 (ru) 1998-03-17 2003-07-20 Ф.Хоффманн-Ля Рош Аг Замещенные бисиндолималеимиды, предназначенные для ингибирования пролиферации клеток

Also Published As

Publication number Publication date
JP2007224048A (ja) 2007-09-06
CO5140077A1 (es) 2002-03-22
RS50193B (sr) 2009-05-06
CZ300215B6 (cs) 2009-03-18
DK0988863T3 (da) 2004-08-30
JP2013035875A (ja) 2013-02-21
AR022096A1 (es) 2002-09-04
YU47399A (es) 2002-08-12
JP6534979B2 (ja) 2019-06-26
NO994583L (no) 2000-03-23
EP0988863A3 (en) 2000-08-09
HU9903189D0 (en) 1999-11-29
JP2000095708A (ja) 2000-04-04
MA26692A1 (fr) 2004-12-20
CZ330499A3 (cs) 2000-04-12
JP2016196515A (ja) 2016-11-24
HUP9903189A3 (en) 2009-07-28
ES2218918T5 (es) 2009-06-23
IL131957A (en) 2005-06-19
NZ337884A (en) 2001-02-23
HUP9903189A2 (hu) 2000-06-28
TR199902324A2 (xx) 2000-04-21
NO326928B1 (no) 2009-03-16
DK0988863T4 (da) 2009-06-08
PL335592A1 (en) 2000-03-27
PT988863E (pt) 2004-07-30
IL131957A0 (en) 2001-03-19
CA2282906A1 (en) 2000-03-22
TR199902324A3 (tr) 2000-04-21
NO994583D0 (no) 1999-09-21
DE69916733T3 (de) 2009-09-24
HU228341B1 (en) 2013-03-28
BR9904283A (pt) 2000-09-26
ID24034A (id) 2000-07-06
AU770745B2 (en) 2004-03-04
PE20001049A1 (es) 2000-10-17
JP2015187170A (ja) 2015-10-29
DE69916733D1 (de) 2004-06-03
HRP990287A2 (en) 2000-06-30
HRP990287B1 (en) 2004-12-31
PL202757B1 (pl) 2009-07-31
JP6253135B2 (ja) 2017-12-27
CN1201821C (zh) 2005-05-18
RU2240827C2 (ru) 2004-11-27
SG97131A1 (en) 2003-07-18
MY124377A (en) 2006-06-30
DE69916733T2 (de) 2005-03-31
KR100362019B1 (ko) 2002-11-23
TWI234465B (en) 2005-06-21
HK1026632A1 (en) 2000-12-22
EP0988863B2 (en) 2009-03-18
US6350786B1 (en) 2002-02-26
SI0988863T2 (sl) 2009-08-31
CA2282906C (en) 2010-07-20
ATE265232T1 (de) 2004-05-15
KR20000023426A (ko) 2000-04-25
EP0988863A2 (en) 2000-03-29
AU4880799A (en) 2000-03-23
CN1251312A (zh) 2000-04-26
SI0988863T1 (en) 2004-08-31
EP0988863B1 (en) 2004-04-28
ES2218918T3 (es) 2004-11-16

Similar Documents

Publication Publication Date Title
AR080892A2 (es) Complejo insoluble en agua, composicion farmaceutica que lo comprende, metodos para prepararla y metodo para preparar dicho complejo
AU2001278471B2 (en) Stable salts of o-acetylsalicyclic with basic amino acids
AR011332A1 (es) Composicion que presenta propiedades de barrera a gases mejorada.
Jesus et al. Highly controlled diffusion drug release from ureasil–poly (ethylene oxide)–Na+–montmorillonite hybrid hydrogel nanocomposites
Bi et al. Temperature responsive self-assembled hydroxybutyl chitosan nanohydrogel based on homogeneous reaction for smart window
BR0211801A (pt) Derivados de 7h-pirrolo[2,3-d]pirimidina
AU8110498A (en) Pharmaceutical formulations containing voriconazole
PL106415B1 (pl) Sposob wytwarzania nowych pochodnych poli/h-/siarczanu poligalaktozydosacharozy
DK153948B (da) Analogifremgangsmaade til fremstilling af vandoploeselige associationsprodukter af (+)-katekin med en aminosyre og eventuelt tillige en anden syre
NO20022591L (no) Finmalt form av (S)-2-etoksy-3-[4-(2-{4- metansulfonyloksyfenyl}etoksy)fenyl]propansyre
Stoica et al. Evaluation of natural polyphenols entrapped in calcium alginate beads prepared by the ionotropic gelation method
ES8103027A1 (es) Un procedimiento para la preparacion de un polipeptido
CN104606680A (zh) 一种负载药物的γ-聚谷氨酸水凝胶的制备方法
Banik et al. Carboxymethyl chitosan‐montmorillonite nanoparticles for controlled delivery of isoniazid: evaluation of the effect of the glutaraldehyde and montmorillonite
CN103214591B (zh) 一种含末端2,5-脱水塔罗糖或其衍生物的低分子量糖胺聚糖衍生物
IL41902A (en) Immunogenic substance,its production,vaccine preparations containing it and their preparation
JPH064679B2 (ja) 粉末状絹フイブロインペプチド及びその製造法
EP0338092A1 (en) Anti-hiv agent
CN114853595B (zh) 一种丙戊酸钠、丙戊酸共晶的制备方法及其产品
PT88158B (pt) Processo para a preparacao de um novo derivado de diosmina
BRPI0013686B8 (pt) procedimento para sintetizar uma mistura de oligossacarídeos
ITFI980104A1 (it) Composizioni stabilizzate contenenti acido ialuronico,loro preparazione ed uso
Yamauchi et al. Development of A Novel Polymeric Prodrug Synthesized Using Plasma-Induced Radicals of Polycrystalline Carbohydrates
JPS54120696A (en) Glucosamine derivative and its preparation
JP2017525654A (ja) 式（ｉ）のコポリマー及び使用

Legal Events

Date Code Title Description
FC Refusal